rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BDTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
      Nov 12Yahoo FinanceBDTX
      Why Is Black Diamond Therapeutics Stock Soaring Tuesday?
      Nov 10BenzingaBDTX
      Black Diamond: Q3 Earnings Snapshot

      (AP) — Black Diamond Therapeutics, Inc. (BDTX) on Tuesday reported a loss of $10 million in its third quarter.

      Nov 10Yahoo FinanceBDTX
      Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC

      Webcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, will host a webcast for investors to present updated results from its ongoing Phase

      Nov 9Yahoo FinanceBDTX
      Black Diamond: Delay In Trial Results Leads To Downgrade, But It's Still A Buy (BDTX)

      Black Diamond Therapeutics maintains a strong cash position, sufficient to fund operations into H2 2028. I rate BDTX stock as Buy. Read my complete analysis.

      Nov 3Seeking AlphaBDTX
      Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?

      Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Sep 4Yahoo FinanceBDTX
      Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

      CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Gl

      Sep 2Yahoo FinanceBDTX
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.

      Aug 28The Globe and MailBDTX

      This is the newest page. Registered accounts read further back.